Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
FHTX Stock News and Mentions of Foghorn Therapeutics Inc. Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Foghorn Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Foghorn Therapeutics Inc. (FHTX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Foghorn Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Foghorn Therapeutics Inc. (FHTX)
April 9, 2024 (20:30) / "GlobeNewswire" (by Foghorn Therapeutics)
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
First-in class BRM ( SMARCA2 ) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically. IND filing on track for ...
In Article Trend: Neutral
April 9, 2024 (20:30) / "Benzinga" (by Globe Newswire)
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs - Foghorn Therapeutics ( NASDAQ:FHTX )
First-in class BRM ( SMARCA2 ) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust preclinical monotherapy anti-tumor activity for both selective CBP and ...
In Article Trend: Neutral
April 8, 2024 (12:00) / "PR Newswire"
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences - PR Newswire
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences PR ...
In Article Trend: Bullish
April 5, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference - Foghorn Therapeutics ( NASDAQ:FHTX )
CAMBRIDGE, Mass., April 05, 2024 ( GLOBE NEWSWIRE ) -- Foghorn® Therapeutics Inc. FHTX, a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 23rd Annual ...
In Article Trend: Neutral
April 2, 2024 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
Does Foghorn Therapeutics ( FHTX ) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
In Article Trend: Somewhat-Bullish
March 19, 2024 (12:30) / "PR Newswire" (by Flagship Pioneering)
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
Ranked #3 Most Innovative Company in North America Recognized for the Third Consecutive Year CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of ...
In Article Trend: Bullish
March 13, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
Foghorn Therapeutics Inc. ( FHTX ) Upgraded to Buy: Here's What You Should Know
Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
In Article Trend: Somewhat-Bullish
March 13, 2024 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. ( FHTX ) : Here's What You Should Know
The consensus price target hints at a 124.3% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
In Article Trend: Somewhat-Bullish
March 7, 2024 (13:20) / "Zacks Commentary" (by Zacks Equity Research)
Foghorn Therapeutics Inc. ( FHTX ) Reports Q4 Loss, Tops Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 27.85% and 17.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 5, 2024 (21:48) / "Benzinga" (by Globe Newswire)
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909 - Foghorn Therapeutics ( NASDAQ:FHTX )
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024 Oral presentation demonstrating preclinical efficacy and tolerability data for Selective CBP and Selective ...
In Article Trend: Neutral
March 5, 2024 (21:48) / "GlobeNewswire" (by Inc.)
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC. IND filing planned in ...
In Article Trend: Neutral
February 28, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
Silence Therapeutics PLC Sponsored ADR ( SLN ) Soars 6.4%: Is Further Upside Left in the Stock?
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
In Article Trend: Somewhat-Bullish
February 28, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference - Foghorn Therapeutics ( NASDAQ:FHTX )
CAMBRIDGE, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Foghorn® Therapeutics Inc.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website